keyword
MENU ▼
Read by QxMD icon Read
search

Surgery ovarian cancer

keyword
https://www.readbyqxmd.com/read/27909274/-three-mitral-valve-operations-in-a-patient-with-trousseau-syndrome-and-nonbacterial-thrombotic-endocarditis-caused-by-ovarian-cancer
#1
Masahito Saito, Naoki Asano, Kazunori Ota, Kazuho Niimi, Koyu Tanaka, Shigeyoshi Gon, Hiroshi Takano
A 52-year-old woman was admitted to our hospital for acute right hemi-paresis, left homonymous hemianopia, and fever. Magnetic resonance imaging of the brain showed multiple cerebral infarctions and transesophageal echocardiography (TEE) revealed a vegetation on the posterior leaflet of her mitral valve. Mitral valve repair was performed under a diagnosis of infective endocarditis (IE). Further multiple cerebral infarctions occurred on the 11th postoperative day, resulting in left hemiplegia and dysarthria...
December 2016: Kyobu Geka. the Japanese Journal of Thoracic Surgery
https://www.readbyqxmd.com/read/27908531/chemotherapy-delay-after-primary-debulking-surgery-for-ovarian-cancer
#2
Brandon-Luke L Seagle, Sharlay K Butler, Anna E Strohl, Wilberto Nieves-Neira, Shohreh Shahabi
OBJECTIVE: To determine the association of chemotherapy delay with overall survival (OS) and investigate predictors of delay among a population-representative American ovarian cancer cohort. METHODS: An observational retrospective cohort analysis of women with ovarian cancer who received National Comprehensive Cancer Network guideline-consistent care was performed with the 1998-2011 National Cancer Data Base. Chemotherapy delay was defined as initiation of multiagent chemotherapy >28days from primary debulking surgery...
November 28, 2016: Gynecologic Oncology
https://www.readbyqxmd.com/read/27906676/role-of-systematic-lymphadenectomy-as-part-of-primary-debulking-surgery-for-optimally-cytoreduced-advanced-ovarian-cancer-reappraisal-in-the-era-of-radical-surgery
#3
Kyung Jin Eoh, Jung-Yun Lee, Jung Won Yoon, Eun Ji Nam, Sunghoon Kim, Sang-Wun Kim, Young Tae Kim
The prognostic significance of pelvic and para-aortic lymphadenectomy during primary debulking surgery for advanced-stage ovarian cancer remains unclear. This study aimed to evaluate the survival impact of lymph node dissection (LND) in patients treated with optimal cytoreduction for advanced ovarian cancer. Data from 158 consecutive patients with stage IIIC-IV disease who underwent optimal cytoreduction (<1 cm) were obtained via retrospective chart review. Patients were classified into two groups: (1) lymph node sampling (LNS), node count <20; and (2) LND, node count ≥20...
November 29, 2016: Oncotarget
https://www.readbyqxmd.com/read/27905089/novel-paradigm-for-immunotherapy-of-ovarian-cancer-by-engaging-prophylactic-immunity-against-hepatitis-b-virus
#4
Marek Malecki, Emily Putzer, Caroline Quach, Chaitanya Dodivenaka, Xenia Tombokan
BACKGROUND: Only eight women out of one hundred diagnosed with ovarian epithelial cancers, which progressed to the clinical stage IV, survive 10 years. First line therapies: surgery, chemotherapy, and radiation therapy inflict very serious iatrogenic consequences. Passive immunotherapy of ovarian cancers offers only low efficacy. Prophylactic and therapeutic vaccines for ovarian cancers are not available. Interestingly, prophylactic vaccines for Hepatitis B Viruses (HBV) are very effective...
December 2016: Clinical and Translational Medicine
https://www.readbyqxmd.com/read/27897153/isoflurane-promotes-non-small-cell-lung-cancer-malignancy-by-activating-the-akt-mammalian-target-of-rapamycin-mtor-signaling-pathway
#5
Wenhua Zhang, Xueqian Shao
BACKGROUND Lung cancer is one of the leading causes of cancer mortalities worldwide, and non-small cell lung cancer (NSCLC) accounts for the majority of all lung cancer cases. Surgery remains one of the front-line treatment options for NSCLC, but events within the perioperative period were found to affect cancer prognosis, such as anesthesia procedures. Isoflurane, a commonly used volatile anesthetic, enhances the malignant potential of renal, prostate, and ovarian cancer cells, but its effects on NSCLC development have not been previously reported...
November 29, 2016: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/27896512/cytoreduction-peritonectomy-procedures-combined-with-hyperthermic-intraperitoneal-chemotherapy-hipec-in-advanced-ovarian-cancer-retrospective-italian-multicenter-observational-study-of-511-cases
#6
Angelo Di Giorgio, Pierandrea De Iaco, Michele De Simone, Alfredo Garofalo, Giovanni Scambia, Antonio Daniele Pinna, Giorgio Maria Verdecchia, Luca Ansaloni, Antonio Macrì, Paolo Cappellini, Valerio Ceriani, Giorgio Giorda, Daniele Biacchi, Marco Vaira, Mario Valle, Paolo Sammartino
PURPOSE: The aim of this study was to help with the process of selecting patients with advanced ovarian cancer to undergo cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) by analyzing outcome data at distinct clinical time points reflecting the natural history of the disease. METHODS: In a retrospective Italian multicenter study investigating patients with advanced ovarian cancer who underwent CRS plus HIPEC between 1998 and 2014, we analyzed data for consecutive patients at eight treatment time points: primary debulking surgery (PDS); interval debulking surgery after partial response, after no response, and after a pathologic complete response to neoadjuvant chemotherapy; first recurrence with a progression-free interval >12, <12 months, or >12 months in patients who underwent further chemotherapy before CRS and HIPEC; and patients who underwent two or more CRS procedures and chemotherapy lines before CRS and HIPEC...
November 28, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27896508/trends-in-mortality-after-primary-cytoreductive-surgery-for-ovarian-cancer-a-systematic-review-and-metaregression-of-randomized-clinical-trials-and-observational-studies
#7
REVIEW
Violante Di Donato, Evangelos Kontopantelis, Giovanni Aletti, Assunta Casorelli, Ilaria Piacenti, Giorgio Bogani, Francesca Lecce, Pierluigi Benedetti Panici
BACKGROUND: Primary cytoreductive surgery (PDS) followed by platinum-based chemotherapy is the cornerstone of treatment and the absence of residual tumor after PDS is universally considered the most important prognostic factor. The aim of the present analysis was to evaluate trend and predictors of 30-day mortality in patients undergoing primary cytoreduction for ovarian cancer. METHODS: Literature was searched for records reporting 30-day mortality after PDS. All cohorts were rated for quality...
November 28, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27896308/small-cell-ovarian-carcinoma-long-term-survival-in-juvenile-case-with-poor-prognostic-features
#8
Lauren Stewart, Ruchi Garg, Rochelle Garcia, Elizabeth Swisher
BACKGROUND: Ovarian small cell carcinoma is a rare, aggressive neoplasm that occurs in young women and has a poor long-term prognosis. Treatment involves surgical resection and chemotherapy. The required radicality of surgery is uncertain, balancing cytoreduction with fertility preservation. Various chemotherapy regimens are utilized due to confusion regarding the neoplasm's lineage. Case We describe an adolescent with small cell carcinoma, hypercalcemic type, stage IA. Surgery included left salpingo-oopherectomy, left pelvic/paraaortic lymphadenectomy, omentectomy and peritoneal biopsies...
November 2016: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/27894705/surgical-treatment-of-early-stage-ovarian-cancer
#9
REVIEW
Jason B Trimbos
The treatment of early-stage (stages I-IIA) ovarian carcinoma is predominantly surgical, and the surgical staging is the most relevant step in the treatment of this disease. The significance of surgical staging is twofold. First, proper staging distinguishes between 'real' early-stage ovarian carcinoma and 'perhaps' early-stage disease. The latter carries an appreciable likelihood of unappreciated residual disease in 16-42% of cases. Second, there is solid proof that proper surgical staging is an independent prognostic factor for improved disease-free and overall survival in early-stage ovarian carcinoma...
October 8, 2016: Best Practice & Research. Clinical Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/27892998/overall-survival-following-neoadjuvant-chemotherapy-vs-primary-cytoreductive-surgery-in-women-with-epithelial-ovarian-cancer-analysis-of-the-national-cancer-database
#10
J Alejandro Rauh-Hain, Alexander Melamed, Alexi Wright, Allison Gockley, Joel T Clemmer, John O Schorge, Marcela G Del Carmen, Nancy L Keating
Importance: Uncertainty remains about the relative benefits of primary cytoreductive surgery (PCS) vs neoadjuvant chemotherapy (NACT) for advanced-stage epithelial ovarian cancer (EOC). Objective: To compare overall survival of PCS vs NACT in a large national population of women with advanced-stage EOC. Design, Setting, and Participants: Retrospective cohort study of women with stage IIIC and IV EOC diagnosed between 2003 and 2011 treated at hospitals across the United States reporting to the National Cancer Data Base...
November 17, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27891812/hudson-s-landmark-contribution-to-ovarian-cancer-surgery
#11
C William Helm
No abstract text is available yet for this article.
December 2016: BJOG: An International Journal of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/27891525/a-validation-study-of-administrative-claims-data-to-measure-ovarian-cancer-recurrence-and-secondary-debulking-surgery
#12
Jennifer Livaudais-Toman, Natalia Egorova, Rebeca Franco, Monica Prasad-Hayes, Elizabeth A Howell, Juan Wisnivesky, Nina A Bickell
OBJECTIVE: Administrative claims data offer an alternative to chart abstraction to assess ovarian cancer recurrence, treatment and outcomes. Such analyses have been hindered by lack of valid recurrence and treatment algorithms. In this study, we sought to develop claims-based algorithms to identify ovarian cancer recurrence and secondary debulking surgery, and to validate them against the gold-standard of chart abstraction. METHODS: We conducted chart validation studies; 2 recurrence algorithms and 1 secondary surgery among 94 ovarian cancer patients treated at one hospital between 2003-2009...
2016: EGEMS
https://www.readbyqxmd.com/read/27890326/the-effect-of-metabolic-comorbidities-and-commonly-used-drugs-on-the-prognosis-of-patients-with-ovarian-cancer
#13
Daniel Bar, Ofer Lavie, Nili Stein, Ido Feferkorn, Ayelet Shai
BACKGROUND: Diabetes mellitus is associated with an increased risk of recurrence in patients with ovarian cancer. Retrospective studies suggested that the use of statins, metformin and beta blockers is associated with improved prognosis in these patients. Patients with diabetes often suffer from hypertension and are usually treated concomitantly by several classes of drugs. Our aim was to assess the independent contribution of diabetes mellitus and hypertension and of the use of aspirin, statins, metformin and beta blockers on the risk of ovarian cancer recurrence and mortality...
October 14, 2016: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/27889016/is-it-necessary-to-perform-routine-appendectomy-for-mucinous-ovarian-neoplasms-a-retrospective-study-and-meta-analysis
#14
REVIEW
Aoshuang Cheng, Minghao Li, Margaux J Kanis, Ying Xu, Qing Zhang, Baoxia Cui, Jie Jiang, YouZhong Zhang, Xingsheng Yang, Beihua Kong
OBJECTIVES: To evaluate whether routine appendectomy is necessary in all patients with mucinous borderline ovarian tumor (mBOT) or mucinous ovarian cancer (MOC) who undergo gynecologic surgery. METHODS: The database of Qilu Hospital was searched for women who underwent appendectomy in a primary surgery for an ovarian tumor between June 2005 and June 2015 and whose final diagnosis was mBOT, MOC or primary appendiceal tumor. A retrospective review was performed, as well as a meta-analysis of the literature to further validate the findings...
November 23, 2016: Gynecologic Oncology
https://www.readbyqxmd.com/read/27888711/preoperative-monocyte-to-lymphocyte-ratio-in-peripheral-blood-predicts-stages-metastasis-and-histological-grades-in-patients-with-ovarian-cancer
#15
Jiangdong Xiang, Lina Zhou, Xing Li, Wei Bao, Taizhong Chen, Xiaowei Xi, Yinyan He, Xiaoping Wan
PURPOSE: The monocyte-to-lymphocyte ratio (MLR) has been shown to be associated with the prognosis of various solid tumors. This study sought to evaluate the important value of the MLR in ovarian cancer patients. METHODS: A total of 133 ovarian cancer patients and 43 normal controls were retrospectively reviewed. The patients' demographics were analyzed along with clinical and pathologic data. The counts of peripheral neutrophils, lymphocytes, monocytes, and platelets were collected and used to calculate the MLR, neutrophil-to-lymphocyte ratio (NLR)...
November 23, 2016: Translational Oncology
https://www.readbyqxmd.com/read/27884789/surgery-for-advanced-epithelial-ovarian-cancer
#16
REVIEW
Neville F Hacker, Archana Rao
Cytoreductive surgery for patients with advanced epithelial ovarian cancer has been practised since the pioneering work of Tom Griffiths in 1975. Further research has demonstrated the prognostic significance of the extent of metastatic disease pre-operatively, and of complete cytoreduction post-operatively. Patients with advanced epithelial ovarian cancer should be referred to high volume cancer units, and managed by multidisciplinary teams. The role of thoracoscopy and resection of intrathoracic disease is presently investigational...
October 20, 2016: Best Practice & Research. Clinical Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/27875625/clinical-and-genetic-determinants-of-ovarian-metastases-from-colorectal-cancer
#17
Karuna Ganesh, Ronak H Shah, Efsevia Vakiani, Garrett M Nash, Hugh P Skottowe, Rona Yaeger, Andrea Cercek, Anne Lincoln, Christina Tran, Neil H Segal, Diane L Reidy, Anna Varghese, Andrew S Epstein, Yukio Sonoda, Dennis Chi, Jose Guillem, Larissa Temple, Philip Paty, Jaclyn Hechtman, Jinru Shia, Martin Weiser, Julio Garcia Aguilar, Nancy Kemeny, Michael F Berger, Leonard Saltz, Zsofia K Stadler
BACKGROUND: Ovarian metastases from colorectal cancer (OM-CRC) often are unresponsive to chemotherapy and are associated with poor survival. To the authors' knowledge, the clinicopathologic and genomic predictors of OM-CRC are poorly characterized and optimal clinical management remains unclear. METHODS: Women with a histopathological diagnosis of OM-CRC who were treated at Memorial Sloan Kettering Cancer Center from 1999 to 2015 were identified. Next-generation somatic mutation profiling (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets [MSK-IMPACT]) was performed on 38 OM-CRC cases, including 21 matched tumor pairs/trios...
November 22, 2016: Cancer
https://www.readbyqxmd.com/read/27874958/diagnostic-accuracy-of-mdct-in-the-evaluation-of-patients-with-peritoneal-carcinomatosis-from-ovarian-cancer-is-delayed-enhanced-phase-really-effective
#18
E Rodolfino, E Devicienti, M Miccò, A Del Ciello, S E Di Giovanni, M Giuliani, C Conte, B Gui, A L Valentini, L Bonomo
OBJECTIVE: To assess the diagnostic accuracy of delayed enhanced phase in addition to portal enhanced phase in MDCT imaging for depicting peritoneal carcinomatosis (PC) implants in patients with ovarian cancer. PATIENTS AND METHODS: We retrospectively reviewed double-phase, portal enhanced phase (PEP) and delayed enhanced phase (DEP), MDCT-examinations of 40 patients with clinical suspicion of recurrent PC from histopathologically-proven ovarian cancer, previously treated with both cytoreductive surgery and adjuvant/neoadjuvant chemotherapy...
November 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/27872532/presentation-and-management-of-inguinal-lymphadenopathy-in-ovarian-cancer
#19
Shveta Giri, Swati H Shah, Kanika Batra, Anu-Bajracharya, Vandana Jain, Himanshu Shukla, Rupinder Sekhon, Sudhir Rawal
The symptoms in ovarian cancer are often missed leading to dubious diagnosis and staging. Inguinal lymphadenopathy (ILAP) is reported to be rare and occurring via lymphatic or hematogenous route. The paucity of studies on ILAP in ovarian cancer indicates a scope of refining its staging and management. The present study aims to document the presentation and management of ILAP in ovarian cancer, which may also reflect its incidence and mechanism of spread. All patients of ovarian cancer with inguinal lymphadenopathy presenting to our institute from 1 January 2015 to 31 December 2015 were included...
December 2016: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27870706/evaluation-of-a-validated-biomarker-test-in-combination-with-a-symptom-index-to-predict-ovarian-malignancy
#20
Renata R Urban, Alan Smith, Kathy Agnew, Vinicius Bonato, Barbara A Goff
OBJECTIVE: This study aimed to evaluate the predictive ability of a multivariate biomarker test in combination with a symptom index (SI) to identify ovarian cancer in a cohort of women planning to undergo surgery for a pelvic mass. METHODS: This was a prospective study of patients seen at a tertiary care medical center. Following consent, patients completed an SI and preoperative serum was collected for a Food and Drug Administration-cleared multivariate biomarker test [multivariate index assay (MIA)]...
November 17, 2016: International Journal of Gynecological Cancer
keyword
keyword
55599
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"